| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $554,000 | 4 | 24 |
Sells | $47,669,545 | 13 | 76 |
| Habiger David C | director | 2 | $251,098 | 0 | $0 | $251,098 |
| LUDWIG EDWARD J | director | 1 | $202,914 | 1 | $424,120 | $-221,206 |
| Pegus Cheryl | director | 1 | $99,987 | 0 | $0 | $99,987 |
| FUJIMORI YOSHIAKI | director | 0 | $0 | 1 | $310,378 | $-310,378 |
| Zane Ellen M | director | 0 | $0 | 3 | $2.57M | $-2.57M |
| Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 0 | $0 | 2 | $3.57M | $-3.57M |
| Mahoney Michael F | Chairman, President & CEO | 0 | $0 | 1 | $15.04M | $-15.04M |
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 0 | $0 | 5 | $25.75M | $-25.75M |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Over the last 12 months, insiders at Boston Scientific Corporation have bought $554,000 and sold $47.67M worth of Boston Scientific Corporation stock.
On average, over the past 5 years, insiders at Boston Scientific Corporation have bought $885,805 and sold $86.69M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Habiger David C (director) — $251,098. LUDWIG EDWARD J (director) — $202,914. Pegus Cheryl (director) — $99,987.
The last purchase of 1,770 shares for transaction amount of $99,987 was made by Pegus Cheryl (director) on 2026‑05‑20.
| 2026-05-20 | LUDWIG EDWARD J | director | 3,580 0.0002% | $56.68 | $202,914 | -13.11% | ||
| 2026-05-20 | Habiger David C | director | 2,250 0.0001% | $55.92 | $125,819 | -13.11% | ||
| 2026-05-20 | Pegus Cheryl | director | 1,770 0.0001% | $56.49 | $99,987 | -13.11% | ||
| 2026-05-19 | Habiger David C | director | 2,200 0.0001% | $56.95 | $125,279 | -12.62% | ||
| 2026-02-02 | Sale | Mahoney Michael F | Chairman, President & CEO | 160,901 0.011% | $93.49 | $15.04M | -30.75% | |
| 2025-12-01 | Sale | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 17,313 0.0012% | $101.55 | $1.76M | -28.67% | |
| 2025-11-06 | Sale | Zane Ellen M | director | 12,891 0.0008% | $98.28 | $1.27M | -24.98% | |
| 2025-11-03 | Sale | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 50,000 0.0033% | $99.47 | $4.97M | -24.35% | |
| 2025-10-28 | Sale | Zane Ellen M | director | 2,901 0.0002% | $102.24 | $296,599 | -25.57% | |
| 2025-10-27 | Sale | Zane Ellen M | director | 9,990 0.0007% | $101.13 | $1.01M | -26.46% | |
| 2025-10-01 | Sale | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 50,000 0.0034% | $98.47 | $4.92M | -13.56% | |
| 2025-09-02 | Sale | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 50,000 0.0033% | $105.43 | $5.27M | -13.27% | |
| 2025-08-01 | Sale | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 50,000 0.0034% | $104.63 | $5.23M | -10.83% | |
| 2025-08-01 | Sale | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 17,313 0.0012% | $104.63 | $1.81M | -10.83% | |
| 2025-07-29 | Sale | FUJIMORI YOSHIAKI | director | 2,901 0.0002% | $106.99 | $310,378 | -11.26% | |
| 2025-07-25 | Sale | LUDWIG EDWARD J | director | 4,000 0.0003% | $106.03 | $424,120 | -10.77% | |
| 2025-07-01 | Sale | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 50,000 0.0035% | $106.97 | $5.35M | -8.50% | |
| 2025-06-04 | Sale | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 56,372 0.0038% | $102.88 | $5.8M | -5.69% | |
| 2025-06-02 | Sale | Mahoney Michael F | Chairman, President & CEO | 164,443 0.0111% | $103.69 | $17.05M | -7.08% | |
| 2025-05-29 | Sale | LUDWIG EDWARD J | director | 4,000 0.0003% | $104.59 | $418,368 | -7.17% |
| Mahoney Michael F | Chairman, President & CEO | 1411735 0.095% | $68.54M | 2 | 29 | +37.05% |
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | 178342 0.012% | $8.66M | 1 | 26 | +12.4% |
| LUDWIG EDWARD J | director | 25359 0.0017% | $1.23M | 2 | 6 | +26.95% |
| Zane Ellen M | director | 24134 0.0016% | $1.17M | 0 | 4 | |
| Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 23600 0.0016% | $1.15M | 0 | 22 | |
| Habiger David C | director | 13878 0.0009% | $673,776.90 | 2 | 0 | |
| FUJIMORI YOSHIAKI | director | 2081 0.0001% | $101,032.55 | 0 | 2 | |
| Pegus Cheryl | director | 1770 0.0001% | $85,933.50 | 1 | 0 | |
| NICHOLAS PETER M | director | 3531021 0.2376% | $171.43M | 0 | 249 | |
| ABELE JOHN E | Director Emeritus | 500000 0.0336% | $24.27M | 5 | 212 | +7.41% |
| Bose Supratim | EVP & President, Asia-Pacific | 320301 0.0215% | $15.55M | 0 | 2 | |
| BEST LAWRENCE C | EVP | 232189 0.0156% | $11.27M | 1 | 24 | <0.0001% |
| Brennan Daniel J. | EVP and CFO | 225808 0.0152% | $10.96M | 0 | 27 | |
| NICHOLAS NJ JR | director | 225000 0.0151% | $10.92M | 20 | 1 | +2.99% |
| Nanavaty Maulik | SVP & Pres, Neuromodulation | 166869 0.0112% | $8.1M | 0 | 22 | |
| Pratt Timothy A. | EVP, GC & Chief Admin Officer | 154681 0.0104% | $7.51M | 0 | 32 | |
| ELLIOTT JOHN RAYMOND | director | 118264 0.008% | $5.74M | 1 | 0 | <0.0001% |
| Kucheman William | Chief Executive Officer | 112525 0.0076% | $5.46M | 3 | 1 | +27.04% |
| Lance Jean Fitterer | SVP, Asst GC, Bus & Regions | 97504 0.0066% | $4.73M | 0 | 10 | |
| Phalen Michael P. | EVP & President, MedSurg | 97910 0.0066% | $4.75M | 0 | 38 | |
| MARIO ERNEST | director | 86032 0.0058% | $4.18M | 22 | 18 | +4.51% |
| Ballinger Kevin J. | EVP & Pres, Interven Cardio | 80085 0.0054% | $3.89M | 0 | 25 | |
| Wang Xin Warren | SVP and Pres, Asia Pacific | 75469 0.0051% | $3.66M | 0 | 4 | |
| Dawkins Keith D | EVP, Global Chief Med. Off. | 68165 0.0046% | $3.31M | 0 | 4 | |
| PEPPER JOHN E | director | 58807 0.004% | $2.86M | 3 | 0 | <0.0001% |
| Pucel Kenneth | EVP, Glob Ops, Qual & Tech | 59000 0.004% | $2.86M | 0 | 1 | |
| TOBIN JAMES R | President and CEO | 50000 0.0034% | $2.43M | 0 | 2 | |
| LAVIOLETTE PAUL A | COO | 49422 0.0033% | $2.4M | 0 | 5 | |
| MCCONNELL WILLIAM F JR | SVP, Administration CRM | 48949 0.0033% | $2.38M | 0 | 2 | |
| Prange Karen | SVP&Pres, Uro & Pelvic Health | 38395 0.0026% | $1.86M | 0 | 6 | |
| MACLEAN ROBERT G | SVP, HR | 36502 0.0025% | $1.77M | 0 | 10 | |
| SANDMAN PAUL W | EVP and General Counsel | 33866 0.0023% | $1.64M | 0 | 4 | |
| Monson Jonathan | SVP, Global Controller and CAO | 34868 0.0023% | $1.69M | 0 | 5 | |
| Sununu John E | director | 32265 0.0022% | $1.57M | 3 | 4 | +4.31% |
| Thepaut Eric Francis Yves | EVP & Pres, Eur, Mid-East, Afr | 31422 0.0021% | $1.53M | 0 | 13 | |
| Brown Vance R | SVP, GC and Corp. Secretary | 31367 0.0021% | $1.52M | 0 | 7 | |
| Bartlett Katharine T | director | 29708 0.002% | $1.44M | 1 | 0 | +4.24% |
| Carruthers Wendy | EVP, Human Resources | 29308 0.002% | $1.42M | 0 | 46 | |
| Meredith Ian T | EVP Global Chief Med Officer | 28082 0.0019% | $1.36M | 0 | 2 | |
| Connors Nelda J | director | 27246 0.0018% | $1.32M | 1 | 4 | <0.0001% |
| WICHMANN DAVID S | director | 25000 0.0017% | $1.21M | 1 | 0 | +0.3% |
| Mirviss Jeffrey B. | EVP&Pres, Periph Intervent | 25766 0.0017% | $1.25M | 0 | 48 | |
| Mackey Edward F | EVP, Operations | 23722 0.0016% | $1.15M | 0 | 3 | |
| Eddy Jodi Euerle | SVP, Chief Info & Digital Off. | 23263 0.0016% | $1.13M | 0 | 8 | |
| Sorenson John Bradley | EVP, Global Operations | 18705 0.0013% | $908,127.75 | 0 | 35 | |
| Scanlon Meghan | SVP,Pres,Urology Pelvic Health | 19142 0.0013% | $929,344.10 | 0 | 2 | |
| FLEISHMAN JOEL LAWRENCE | director | 18250 0.0012% | $886,037.50 | 1 | 0 | +1.14% |
| Olson Scott | SVP & Pres, CRM, Diagnostics | 14518 0.001% | $704,848.90 | 0 | 6 | |
| BURNS URSULA M | director | 13500 0.0009% | $655,425.00 | 4 | 0 | <0.0001% |
| Ralls-Morrison Desiree | SVP, GC and Corp Secretary | 11450 0.0008% | $555,897.50 | 0 | 3 | |
| TAYLOR JAMES H JR | Sr. VP, Operations | 9360 0.0006% | $454,428.00 | 0 | 4 | |
| MORECI STEPHEN F | SVP, Global Sales Operations | 7216 0.0005% | $350,336.80 | 1 | 7 | <0.0001% |
| REINHARDT UWE E | director | 5000 0.0003% | $242,750.00 | 3 | 1 | <0.0001% |
| Goodman Jeffrey H | SVP, International | 5000 0.0003% | $242,750.00 | 2 | 0 | <0.0001% |
| FOX MARYE ANNE | director | 3305 0.0002% | $160,457.75 | 1 | 0 | +18.63% |
| GROVES RAY J | director | 1000 0.0001% | $48,550.00 | 3 | 0 | <0.0001% |
| BARTELL MARK C | SVP Global Sales/Mkt CRM | 1812 0.0001% | $87,972.60 | 0 | 1 | |
| Burns Brian R | EVP - Global Quality & Reg Aff | 1289 0.0001% | $62,580.95 | 0 | 1 | |
| JOHNSON KRISTINA M | director | 0 0% | $0 | 0 | 3 | |
| DEPARLE NANCY ANN | director | 0 0% | $0 | 0 | 2 | |
| COLEN FRED | EVP & Chief Technology Officer | 0 0% | $0 | 0 | 18 | |
| CAPELLO JEFFREY D | EVP & Chief Financial Officer | 447 0% | $21,701.85 | 0 | 5 | |
| Russell Mary E | SVP and CMO | 0 0% | $0 | 0 | 2 | |
| Dockendorff Charles J | director | 0 0% | $0 | 1 | 2 | +35.4% |
| Pedersen John B. | Pres, Uro & Women's Health | 0 0% | $0 | 0 | 3 | |
| Pierce David A | EVP Pres MedSurg | 0 0% | $0 | 0 | 88 | |
| Woodworth Emily | SVP, Global Controller and CAO | 432 0% | $20,973.60 | 0 | 4 |
| Increased Positions | 919 | +49.04% | 110M | +8.09% |
| Decreased Positions | 836 | -44.61% | 95M | -7.01% |
| New Positions | 219 | New | 25M | New |
| Sold Out Positions | 137 | Sold Out | 6M | Sold Out |
| Total Postitions | 1,957 | +4.43% | 1B | +1.08% |
| Blackrock, Inc. | $13.75M | 9.8% | 145.18M | -2M | -1.03% | 2025-09-30 |
| Vanguard Group Inc | $13.09M | 9.33% | 138.25M | +1M | +0.81% | 2025-09-30 |
| Fmr Llc | $9.42M | 6.71% | 99.48M | -9M | -8.15% | 2025-09-30 |
| State Street Corp | $6.15M | 4.38% | 64.93M | -266,300 | -0.41% | 2025-09-30 |
| Bank Of America Corp /De/ | $3.21M | 2.29% | 33.87M | +23,922 | +0.07% | 2025-09-30 |
| Primecap Management Co/Ca/ | $3.14M | 2.23% | 33.1M | -2M | -4.5% | 2025-09-30 |
| Geode Capital Management, Llc | $3.1M | 2.21% | 32.69M | +265,546 | +0.82% | 2025-09-30 |
| Jpmorgan Chase & Co | $2.68M | 1.91% | 28.33M | +3M | +10.4% | 2025-09-30 |
| Capital World Investors | $2.52M | 1.8% | 26.65M | -2M | -6.58% | 2025-09-30 |
| Morgan Stanley | $1.96M | 1.4% | 20.71M | +450,584 | +2.22% | 2025-09-30 |